Progress Software Corporation shares rise 2.62% intraday amid biotech sector growth and AI-driven innovation.

Progress Software Corporation rose 2.62% intraday, with the biotechnology sector entering a dynamic growth phase, fueled by advances in gene therapy, AI-assisted drug discovery, and personalized medicine. Global biotech revenue is projected to grow from $1.55 trillion in 2024 to over $4.6 trillion by 2034, reflecting a surge in both investment and innovation. Venture funding is rebounding strongly, with billions pouring into early-stage companies developing transformative therapies.